DK3225627T5 - Tripeptidforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf - Google Patents
Tripeptidforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf Download PDFInfo
- Publication number
- DK3225627T5 DK3225627T5 DK15863217.4T DK15863217T DK3225627T5 DK 3225627 T5 DK3225627 T5 DK 3225627T5 DK 15863217 T DK15863217 T DK 15863217T DK 3225627 T5 DK3225627 T5 DK 3225627T5
- Authority
- DK
- Denmark
- Prior art keywords
- tripeptime
- manufacture
- connection
- tripeptime connection
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410705180.3A CN105693817B (zh) | 2014-11-27 | 2014-11-27 | 一类三肽化合物及其制备方法与应用 |
| PCT/CN2015/095758 WO2016082786A1 (zh) | 2014-11-27 | 2015-11-27 | 一类三肽化合物及其制备方法与应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3225627T3 DK3225627T3 (da) | 2021-11-29 |
| DK3225627T5 true DK3225627T5 (da) | 2022-02-28 |
Family
ID=56073634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15863217.4T DK3225627T5 (da) | 2014-11-27 | 2015-11-27 | Tripeptidforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11358985B2 (da) |
| EP (1) | EP3225627B9 (da) |
| JP (1) | JP6689848B2 (da) |
| KR (1) | KR102098783B1 (da) |
| CN (1) | CN105693817B (da) |
| AU (1) | AU2015353118B2 (da) |
| CA (1) | CA2968595C (da) |
| CY (1) | CY1125043T1 (da) |
| DK (1) | DK3225627T5 (da) |
| ES (1) | ES2897916T3 (da) |
| HK (1) | HK1243437A1 (da) |
| HU (1) | HUE056645T2 (da) |
| IL (1) | IL252448B (da) |
| MY (1) | MY193996A (da) |
| NZ (1) | NZ732301A (da) |
| PL (1) | PL3225627T3 (da) |
| PT (1) | PT3225627T (da) |
| RU (1) | RU2685709C2 (da) |
| SG (1) | SG11201704235SA (da) |
| SI (1) | SI3225627T1 (da) |
| WO (1) | WO2016082786A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107056788A (zh) * | 2017-03-23 | 2017-08-18 | 河南工程学院 | 一种咪唑烷酮类衍生物及其合成方法 |
| CN107337712A (zh) * | 2017-07-26 | 2017-11-10 | 盐城卫生职业技术学院 | 一种抗高血压活性肽Orn‑Hyp‑Pro及应用和药物组合物 |
| CN107337711A (zh) * | 2017-07-26 | 2017-11-10 | 盐城卫生职业技术学院 | 一种抗高血压活性肽Citn‑Pro‑Hyp及应用和药物组合物 |
| CN112830884A (zh) * | 2019-11-22 | 2021-05-25 | 深圳市高盈医药科技开发有限公司 | 一种丹参素衍生物及其制备方法及其医药用途 |
| US20240002359A1 (en) * | 2020-12-03 | 2024-01-04 | Merck Sharp & Dohme Llc | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE252191C (da) | ||||
| IL60888A (en) | 1978-06-16 | 1984-07-31 | Yeda Res & Dev | Substrates and process for the quantitative assay of enzymes |
| DE3315464A1 (de) | 1983-04-28 | 1984-10-31 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von n-alkylierten dipeptiden und deren estern |
| KR900008794B1 (ko) | 1986-06-11 | 1990-11-29 | 티 디 케이 가부시끼가이샤 | 방전 램프장치 |
| DE3619633A1 (de) | 1986-06-11 | 1987-12-17 | Hoechst Ag | Peptide mit einfluss auf die diurese und natriurese, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| DE3839127A1 (de) * | 1988-11-19 | 1990-05-23 | Hoechst Ag | Pyrrolidon-2-carbonsaeure-derivate mit psychotroper wirkung |
| DK0957903T3 (da) * | 1996-09-18 | 2005-11-21 | Applied Genetics Inc Dermatics | Norbornen- og norbornandiolforbindelser til behandling af pigmenteringslidelser, neurodegenerative sygdomme eller proliferative hudlidelser |
| WO2004024754A1 (ja) | 2002-09-11 | 2004-03-25 | Toaeiyo Ltd. | プロリンエステル類及びそれを含有する経皮投与製剤 |
| GB2395195A (en) | 2002-11-18 | 2004-05-19 | Cipla Ltd | Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors |
| PT1669463E (pt) | 2003-08-01 | 2009-01-23 | Calpis Co Ltd | Hidrolisado de caseína, processo para produção do mesmo e sua utilização |
| CN1939912A (zh) * | 2005-10-01 | 2007-04-04 | 代斌 | N－[2－(3－苯基－2－丙烯酰氨基)丙酰基]－噻唑烷酸及其衍生物制备方法 |
| CN100415709C (zh) | 2006-05-15 | 2008-09-03 | 西北大学 | β-(3,4-二羟基苯基)-α-羟基丙酸冰片酯、其合成方法和用途 |
| BRPI1007600A2 (pt) | 2009-04-23 | 2019-09-24 | Invasc Therapeutics Inc | composições e métodos para tratamento de doenças cardiovasculares |
| CN101607907B (zh) * | 2009-06-22 | 2013-01-23 | 西北大学 | 取代的苯甲酸衍生物及其合成方法和用途 |
| JP5799842B2 (ja) | 2012-02-03 | 2015-10-28 | 秋田県 | アンジオテンシン変換酵素阻害ペプチド、該ペプチドを含有するアンジオテンシン変換酵素阻害剤、組成物及び食品、並びに、該ペプチドの製造方法 |
| CN102757479B (zh) | 2012-05-09 | 2014-04-30 | 北京林业大学 | 高活性降血压肽及其制备方法 |
| JP2014141462A (ja) | 2012-12-27 | 2014-08-07 | Raffinee International Co Ltd | ペプチド、並びに、アンジオテンシン変換酵素阻害剤、抗高血圧剤、及び飲食品 |
| CN104945469B (zh) * | 2015-06-30 | 2018-09-28 | 石狮海星食品有限公司 | Ace抑制三肽 |
-
2014
- 2014-11-27 CN CN201410705180.3A patent/CN105693817B/zh active Active
-
2015
- 2015-11-27 AU AU2015353118A patent/AU2015353118B2/en active Active
- 2015-11-27 CA CA2968595A patent/CA2968595C/en active Active
- 2015-11-27 PL PL15863217T patent/PL3225627T3/pl unknown
- 2015-11-27 KR KR1020177017351A patent/KR102098783B1/ko active IP Right Grant
- 2015-11-27 SI SI201531768T patent/SI3225627T1/sl unknown
- 2015-11-27 RU RU2017121590A patent/RU2685709C2/ru active
- 2015-11-27 MY MYPI2017701895A patent/MY193996A/en unknown
- 2015-11-27 EP EP15863217.4A patent/EP3225627B9/en active Active
- 2015-11-27 SG SG11201704235SA patent/SG11201704235SA/en unknown
- 2015-11-27 ES ES15863217T patent/ES2897916T3/es active Active
- 2015-11-27 HU HUE15863217A patent/HUE056645T2/hu unknown
- 2015-11-27 PT PT158632174T patent/PT3225627T/pt unknown
- 2015-11-27 JP JP2017527865A patent/JP6689848B2/ja active Active
- 2015-11-27 WO PCT/CN2015/095758 patent/WO2016082786A1/zh active Application Filing
- 2015-11-27 NZ NZ732301A patent/NZ732301A/en unknown
- 2015-11-27 US US15/529,633 patent/US11358985B2/en active Active
- 2015-11-27 DK DK15863217.4T patent/DK3225627T5/da active
-
2017
- 2017-05-23 IL IL252448A patent/IL252448B/en active IP Right Grant
-
2018
- 2018-03-01 HK HK18102948.9A patent/HK1243437A1/zh unknown
-
2021
- 2021-11-11 CY CY20211100983T patent/CY1125043T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017121590A (ru) | 2018-12-27 |
| EP3225627A1 (en) | 2017-10-04 |
| NZ732301A (en) | 2018-05-25 |
| RU2685709C2 (ru) | 2019-04-23 |
| JP2018505847A (ja) | 2018-03-01 |
| AU2015353118B2 (en) | 2018-12-13 |
| PL3225627T3 (pl) | 2022-02-28 |
| IL252448B (en) | 2019-09-26 |
| WO2016082786A1 (zh) | 2016-06-02 |
| KR20170087497A (ko) | 2017-07-28 |
| US20170267718A1 (en) | 2017-09-21 |
| RU2017121590A3 (da) | 2018-12-27 |
| EP3225627A4 (en) | 2018-08-22 |
| ES2897916T3 (es) | 2022-03-03 |
| KR102098783B1 (ko) | 2020-04-10 |
| SG11201704235SA (en) | 2017-06-29 |
| PT3225627T (pt) | 2021-11-17 |
| US11358985B2 (en) | 2022-06-14 |
| CY1125043T1 (el) | 2023-06-09 |
| IL252448A0 (en) | 2017-07-31 |
| DK3225627T3 (da) | 2021-11-29 |
| CN105693817A (zh) | 2016-06-22 |
| JP6689848B2 (ja) | 2020-04-28 |
| CA2968595C (en) | 2019-09-24 |
| CA2968595A1 (en) | 2016-06-02 |
| SI3225627T1 (sl) | 2022-02-28 |
| EP3225627B9 (en) | 2022-01-05 |
| CN105693817B (zh) | 2020-06-05 |
| HK1243437A1 (zh) | 2018-07-13 |
| MY193996A (en) | 2022-11-07 |
| EP3225627B1 (en) | 2021-11-03 |
| HUE056645T2 (hu) | 2022-02-28 |
| AU2015353118A1 (en) | 2017-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
| DK3201351T3 (da) | Kaloriefrie sødestoffer og fremgangsmåder til syntetisering | |
| DK3212189T3 (da) | Substituerede chromaner og fremgangsmåde til anvendelse deraf | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3152956T3 (da) | Systemer og metoder til kommunikation | |
| DK3209308T3 (da) | Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf | |
| DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3227336T3 (da) | Anti-CD79b-antistoffer og fremgangsmåder til anvendelse | |
| DK3205650T3 (da) | Egfr-hæmmer og fremstilling og anvendelse deraf | |
| DK3265947T3 (da) | Fremgangsmåde og system til kryptering | |
| DK3212255T3 (da) | Selvorienterende sprøjte og sprøjtegrænseflade | |
| DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| DK3229838T3 (da) | Anti-C10orf54-antistoffer og anvendelser deraf | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3161693T3 (da) | System og fremgangsmåde til overvågning | |
| DK3319612T3 (da) | Oxysteroler og fremgansmåder til anvendelse derfor | |
| DK3113797T3 (da) | Antistoffer, anvendelser og fremgangsmåder | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| DK3116911T3 (da) | Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse | |
| DK3074544T3 (da) | Martensitholdigt rustfrit stål, stykke udført i dette stål og fremgangsmåde til fremstilling heraf | |
| DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
| DK3178324T3 (da) | Mikrobicid og fremgangsmåde til fremstilling af samme | |
| DK3368578T3 (da) | Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf |